

"Express Mail" Label No. EV 325767600US

Date of Deposit 1.14.04

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

**Mail Stop RCE**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By:

*Tara N. Damhoff*  
Tara N. Damhoff

Attorney Docket No.: 020054-001130US

**RECEIVED**  
PATENT  
JAN 22 2004  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Peter S. Lu et al.

Application No.: 09/724,553

Filed: November 28, 2000

For: MOLECULAR INTERACTIONS  
IN T-LYMPHOCYTES  
(AMENDED)

Customer No.: 20350

Confirmation No.: 7232

Examiner: Belyavskiy, Michail A.

Art Unit: 1644

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

**Mail Stop RCE**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb  
47111928 v1



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 2

**Complete if Known**

Application Number	09/724,553
Filing Date	November 28, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy
Attorney Docket Number	020054-001130US

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Bals, Robert et al. "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide" <i>Infection and Immunity</i> , Nov. 1999, pp. 6084-6089, Vol. 67, No. 11.	
	C2	Bruyns, E. et al. "Identification of the Sites of Interaction between Lymphocyte Phosphatase-associated Phosphoprotein (LPAP) and CD45", <i>Journal of Biological Chemistry</i> , December 29, 1996, pp. 31372-31376, Vol. 270, No. 52, U.S.A.	
	C3	Coligan, John et al. "Antibody Detection and Preparation" <i>Current Protocols in Immunology</i> , Supplement 1, 1991, pp.2.0.1-2.1.18	
	C4	Ding, I. Et al., "Biochemical and Functional Analysis of Mice Deficient in Expression of the CD45-Associated Phosphoprotein LPAP", <i>European Journal of Immunology</i> , 29(12):3956-61 (1999).	
	C5	Gee, S.H. et al., "Interaction of Muscle and Brain Sodium Channels with Multiple Members of the Syntrophin Family of Dystrophin-Associated Proteins", <i>J. Neuroscience</i> , 18(1):128-137, (1998).	
	C6	Gee, S.H., et al., "Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains", <i>The Journal of Biological Chemistry</i> , 273(34):21980-21987, (1998).	
	C7	Hanada, T., et al., "Human Homologue of the Drosophila Discs Large Tumor Suppressor Binds to p56 <sup>lck</sup> Tyrosine Kinase and Shaker Type Kv1.3 Potassium Channel in T. Lymphocytes", <i>The Journal of Biological Chemistry</i> , 272(43):26899-26904, (1997).	
	C8	Kobayashi, I., et al., "Identification of an Autoimmune Enteropathy-related 75-kilodalton Antigen", <i>Gastroenterology</i> , October 1999, pp. 823-830, Vol. 117, No. 4.	
	C9	Maekawa, K., et al., "Association of Protein-Tyrosine Phosphatase PTP-BAS with the Transcription-factor-inhibitory Protein I $\kappa$ B $\alpha$ Through Interaction Between the PDZ1 Domain and Ankyrin Repeats", <i>Biochemical Journal</i> , 337(2):179-187, (1999).	
	C10	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain", <i>DNA Research</i> , 1996, pp. 321-329, Vol. 3.	
	C11	Nishihara, H. et al. "Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins", <i>Biochimica et Biophysica Acta</i> , 1999, pp. 179-187, Elsevier Publishing.	
	C12	Nishihara, H. "Analysis of Hematopoietic Cell Specific Protein, M-DOCK", <i>Hokkaido Igaku Zasshi</i> , March 1999, p. 157-166, Vol. 74, No. 2.	
	C13	Saras, J., et al., "PDZ Domains Bind Carboxy-Terminal Sequences of Target Proteins", <i>Trends in Biochemical Sciences</i> , 1996, Elsevier Publication, Cambridge, 21(12):455-458, (1996).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of 2

**Complete if Known**

Application Number	09/724,553
Filing Date	November 28, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy
Attorney Docket Number	020054-001130US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C14	Schepens, J., et al., "The Neuronal Nitric Oxide Synthase PDZ Motif Binds to -G(D.E)XV Carboxy Terminal Sequences", <i>Febs Letters</i> , 409(1-2):53-56, (1997).	
	C15	Schraven, Burkhardt et al. "LPAP, a Novel 32-kDa Phosphoprotein That Interacts with CD45 in Human Lymphocytes", <i>J. Biological Chemistry</i> , November 18, 1994; Vol. 269, No. 46, pp. 29102-29111.	
	C16	Shibuya, A., et al., "DNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes", <i>Immunity</i> , 4:573-581, (1996).	
	C17	Shibuya, A., et al., "Protein Kinase C is Involved in the Regulation of Both Signaling and Adhesion Mediated by DNAX Accessory Molecule-1 Receptor", <i>The Journal of Immunology</i> , 161:1671-1676, (1998).	
	C18	Shibuya, K., et al., "Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule", <i>Immunity</i> , 11:615-623, (1999).	
	C19	Yanagisawa, J., et al., "The Molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis", <i>J. Biol. Chem.</i> , 272(13):8539-8545, (1997).	
	C20	Genbank, Accession Number AF028823, 12/01/1999	
	C21	GenBank, Accession Number BM845132, 03/06/2002	
	C22	GenBank, Accession Number CB131761, 01/29/2003	
	C23	GenBank, Accession Number CB961389, 04/28/2003	
	C24	GenBank, Accession Number CB995033, 04/30/2003	
	C25	Genbank, Accession Number D86964, 02/07/1999	
	C26	OMIM Database entry entitled, '147138 Fc Fragment of IgE, High Affinity I, Receptor for, Beta Subunit; FCER1B', www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmm?147138, 08/27/1992 Victor A. McKusick.	
	C27	OMIM Database entry entitled, "603122 Dedicator of Cytokinesis 2; Dock 2" www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmm?603122, 10/12/1998 Rebekah S. Rasooly.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.